Disclosure of Unlabeled Use and Disclaimer:

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute for Medicine (PIM), or Jazz Pharmaceuticals. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use (review of any applicable manufacturer's product information), and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.

Faculty

Marin Abousaud, PharmD, BCOP

Oncology Clinical Pharmacy Specialist
Emory Healthcare
Atlanta, Georgia

The opinions expressed are those of Dr. Abousaud and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr. Abousaud's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Disclosures

Marin Abousaud, PharmD, BCOP, has no relevant financial relationships.

Beth Sandy, MSN, CRNP

Thoracic Oncology Nurse Practitioner
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania

Disclosures

Beth Sandy, MSN, CRNP, has the following relevant financial relationships:
Consultant or advisor for: Janssen
Other: non-CE Services fees from Amgen; AstraZeneca; Jazz Pharmaceuticals; Merck & Co.; Takeda.

The clinical reviewer, Megan May PharmD, BCOP, has no relevant affiliations or financial relationships with a commercial interest.

The medical writer, Larry Rosenberg, has no actual or potential conflicts of interest in relation to this program.

Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities, hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

The PIM planners and others have no relevant affiliations or financial relationships.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

CE

Pathways in the Management of Extensive-Stage SCLC: Shifting Strategies and Optimizing Outcomes

Authors: Marin Abousaud, PharmD, BCOP; Beth Sandy, MSN, CRNP
CE Released: 11/30/2022; Reviewed and Renewed: 2/20/2023
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 5/30/2023

Start Activity

Target Audience and Goal Statement

This activity is intended for oncology nurses and nurse practitioners, and oncology and managed care pharmacists.

Provide up-to-date knowledge of the evolving extensive-stage small cell lung cancer (ES-SCLC) treatment landscape, optimal toxicity prevention and management, and enhanced pharmaceutical care.

Upon completion of this activity, participants will:

Identify the mechanisms of action of newer and emerging agents utilized in the management of ES-SCLC
Assess the efficacy and safety of newer and emerging therapies for the treatment of ES-SCLC
Formulate collaborative approaches to determine the most appropriate SCLC treatment regimen based on patient-specific characteristics

Disclosures

Disclosure of Unlabeled Use and Disclaimer:

Faculty

Marin Abousaud, PharmD, BCOP

Oncology Clinical Pharmacy Specialist
Emory Healthcare
Atlanta, Georgia

The opinions expressed are those of Dr. Abousaud and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr. Abousaud's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Disclosures

Marin Abousaud, PharmD, BCOP, has no relevant financial relationships.

Beth Sandy, MSN, CRNP

Thoracic Oncology Nurse Practitioner
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania

Disclosures

Beth Sandy, MSN, CRNP, has the following relevant financial relationships:
Consultant or advisor for: Janssen
Other: non-CE Services fees from Amgen; AstraZeneca; Jazz Pharmaceuticals; Merck & Co.; Takeda.

The clinical reviewer, Megan May PharmD, BCOP, has no relevant affiliations or financial relationships with a commercial interest.

The medical writer, Larry Rosenberg, has no actual or potential conflicts of interest in relation to this program.

The PIM planners and others have no relevant affiliations or financial relationships.

All relevant financial relationships have been mitigated.

Accreditation Statements

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Nurses

The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours. Designated for 0.75 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Published: November 18, 2022

Expires: May 18, 2023

Type of Activity: Application

Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 120 minutes

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

processing....

References

American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022. Accessed September 30, 2022. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf
PDQ Adult Treatment Editorial Board. Small Cell Lung Cancer Treatment (PDQ®): Health Professional Version. In: PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); April 14, 2022.
Gong J, Salgia R. Managing patients with relapsed small-cell lung cancer J Oncol Pract. 2018;14(6):359-366.
Johal S, Hettle R, Carroll J, et al. Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review. J Thorac Dis. 2021;13(6):3692-3707.
Enstone A, Greaney M, Povsic M, et al. The economic burden of small cell lung cancer: a systematic review of the literature. Pharmacoecon Open. 2018;2(2):125-139.
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Small cell carcinoma of the lung and bronchus. Available at: https://seer.cancer.gov/. Accessed September 30, 2022.
Yuan M, Zhao Y, Arkenau HT, et al. Signal pathways and precision therapy of small-cell lung cancer. Signal Transduct Target Ther. 2022;7(1):187.
Lazzari C, Mirabile A, Bulotta A, et al. History of extensive disease small cell lung cancer treatment: time to raise the bar? A review of the literature. Cancers (Basel). 2021;13(5):998.
Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539-4544.
Nicholson AG, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(3):300-311.
Arriola E, Trigo JM, Sánchez-Gastaldo A, et al. Prognostic value of clinical staging according to TNM in patients with SCLC: a real-world surveillance epidemiology and end-results database analysis. JTO Clin Res Rep. 2021;3(1):100266.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Small Cell Lung Cancer Version 2.2022 — November 24, 2021. Available at: https://www.nccn.org/ Accessed September 30, 2022.
Martucci F, Pascale M, Valli MC, et al. Impact of 18F-FDG PET/CT in staging patients with small cell Lung cancer: a systematic review and meta-analysis. Front Med (Lausanne). 2020;6:336.
Oronsky B, Abrouk N, Caroen S, et al. A 2022 update on extensive stage small-cell lung cancer (SCLC). J Cancer. 2022;13(9):2945-2953.
Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol. 1990;8:1563-1574.
Foster NR, Mandrekar SJ, Schild SE, et al. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2009;115:2721-2731.
Iams WT, Shiuan E, Meador CB, et al. Improved prognosis and increased tumor-infiltrating lymphocytes in patients who have SCLC with neurologic paraneoplastic syndromes. J Thorac Oncol. 2019;14(11):1970-1981.
Christensen TN, Andersen PK, Langer SW, Fischer BMB. Prognostic value of 18F-FDG-PET parameters in patients with small cell lung cancer: a meta-analysis and review of current literature. Diagnostics (Basel). 2021;11(2):174.
El Sayed R, Blais N. Immunotherapy in extensive-stage small cell lung cancer. Curr Oncol. 2021;28(5):4093-4108.
Denninghoff V, Russo A, de Miguel-Pérez D, et al. Small cell lung cancer: state of the art of the molecular and genetic landscape and novel perspective. Cancers (Basel). 2021;13(7):1723.
Marcoux N, Gettinger SN, O'Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: Clinical outcomes. J Clin Oncol. 2019;37(4):278-285.
Schwendenwein A, Megyesfalvi Z, Barany N, et al. Molecular profiles of small cell lung cancer subtypes: therapeutic implications. Mol Ther Oncolytics. 2021;20:470-483.
Ushio R, Murakami S, Saito H. Predictive markers for immune checkpoint inhibitors in non-small cell lung cancer. J Clin Med. 2022;11(7):1855.
Zhang B, Birer SR, Dvorkin M, Shruti J, Byers L. New therapies and biomarkers: Are we ready for personalized treatment in small cell lung cancer?. Am Soc Clin Oncol Educ Book. 2021;41:1-10.
Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34:3740-3748.
Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol. 1994;5(7):601-607.
Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007;97(2):162-169.
Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692-1698.
Hatfield LA, Huskamp HA, Lamont EB. Survival and toxicity after cisplatin plus etoposide versus carboplatin plus etoposide for extensive-stage small-cell lung cancer in elderly patients. J Oncol Pract. 2016;12(7):666-673.
Powell K, Prasad V. Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer. Transl Oncol. 2021;14(11):101206.
Hussein M, Maglakelidze M, Richards DA, et al. Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: pooled results from three phase 2, randomized, double-blind, placebo-controlled studies. Cancer Manag Res. 2021;13:6207-6218.
Hiddinga BI, Raskin J, Janssens A, et al. Recent developments in the treatment of small cell lung cancer. Eur Respir Rev. 2021;30(161):210079.
Zugazagoitia J, Paz-Ares L. Extensive-stage small-cell lung cancer: first-line and second-line treatment options. J Clin Oncol. 2022;40(6):671-680.
Petrelli F, Ghidini A, Luciani A. Topotecan or other agents as second-line therapy for relapsed small-cell lung cancer: A meta-analysis of randomized studies. Mol Clin Oncol. 2021;15(4):218.
von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658-667.
Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 2011;29(3):287-293.
OPDIVO® (nivolumab) prescribing information. Bristol-Myers Squibb, Princeton, NJ, May 2022.
KEYTRUDA® (pembrolizumab) prescribing information. Merck & Co., Whitehouse Station, NJ, February 2022.
TECENTRIQ® (atezolizumab) prescribing information. Genentech, South San Francisco, CA, January 2022.
IMFINZI® (durvalumab) prescribing information. AstraZeneca Pharmaceuticals, Wilmington, DE, October2022.
YERVOY® (ipilimumab) prescribing information. Bristol-Myers Squibb, Princeton, NJ, May 2022.
Dumoulin DW, Dingemans AC, Aerts JGJV, et al. Immunotherapy in small cell lung cancer: one step at a time: a narrative review. Transl Lung Cancer Res. 2021;10(6):2970-2987.
Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500-2501.
Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-2229.
Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619-630.
TECENTRIQ® (atezolizumab) prescribing information. Genentech, South San Francisco, CA, June 2018.
Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51-65.
IMFINZI® (durvalumab) prescribing information. AstraZeneca Pharmaceuticals, Wilmington, DE, September 2022.
Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2):100408.
Riano I, Patel SR, Liu SV, Duma N. Evidence to date: Evaluating pembrolizumab in the treatment of extensive-stage small-cell lung cancer. Clin Pract. 2021;11(3):441-454.
Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369-2379.
Rudin CM, Kim HR, Navarro A, et al. First-line pembrolizumab or placebo combined with etoposide and platinum for ES-SCLC: KEYNOTE-604 long-term follow-up results. Presented at the IASLC 2022 World Conference on Lung Cancer, Vienna, Austria, August 6-9, 2022 (abstr OA12.06).
ClinicalTrials.gov. Pembrolizumab/vibostolimab (MK-7684A) or atezolizumab in combination with chemotherapy in first line treatment of extensive-stage small cell lung cancer (MK-7684A-008, KEYVIBE-008). Available at: https://clinicaltrials.gov/ct2/show/NCT05224141 Accessed September 30, 2022.
Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: A phase 3 randomized clinical trial. JAMA Oncol. 2021;7:709-717.
Lum C, Alamgeer M. Technological and therapeutic advances in advanced small cell lung cancer. Cancers (Basel). 2019;11(10):1570.
Ready NE, Ott PA, Hellmann MD, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: Results from the CheckMate 032 randomized cohort. J Thorac Oncol. 2020;15(3):426-435.
Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol. 2021;32(5):631-641.
Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15(4):618-627.
The ASCO Post. Nivolumab indication in small cell lung cancer withdrawn in U.S. market. Available at: https://ascopost.com/ Accessed September 30, 2022.
The ASCO Post. Pembrolizumab's indication in small cell lung cancer is withdrawn. Available at: https://ascopost.com/ Accessed September 30, 2022.
Owonikoko TK, Park K, Govindan R, et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol. 2021;39(12):1349-1359.
Wang Z, Zhao J, Ma Z, et al. A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients [published correction appears in Lung Cancer. 2021;158:166-167]. Lung Cancer. 2020;147:259-268.
ClinicalTrials.gov. Study of platinum plus etoposide with or without BGB-A317 in participants with untreated extensive-stage small cell lung cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT04005716. Accessed September 30, 2022.
ClinicalTrials.gov. Tislelizumab in combination with anlotinib with ES-SCLC as maintenance therapy after first line chemotherapy. Available at: https://clinicaltrials.gov/ct2/show/NCT0462083. Accessed September 30, 2022.
Xu Y, Cui G, Jiang Z, Li N, Zhang X. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors. Oncol Lett. 2019;17(3):2960-2968.
Cho BC, Abreu DR, Hussein M, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781-792.
Rudin CM, Liu SV, Lu S, et al. SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC). J Clin Oncol. 2022;40 (suppl; LBA8507).
ClinicalTrials.gov. A study of atezolizumab plus carboplatin and etoposide with or without tiragolumab in patients with untreated extensive-stage small cell lung cancer (SKYSCRAPER-02). Available at: https://clinicaltrials.gov/ct2/show/NCT04256421 Accessed September 30, 2022.
Baena J, Modrego A, Zeaiter A, et al. Lurbinectedin in the treatment of relapsed small cell lung cancer. Future Oncol. 2021;17(18):2279-2289.
Paz-Ares LG, Perez JMT, Besse B, et al. Efficacy and safety profile of lurbinectedin in second-line SCLC patients: results from a phase II single-agent trial. J Clin Oncol. 2019;37 (suppl; abstr 8506).
Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial [published correction appears in Lancet Oncol. 2020;21(12):e553]. Lancet Oncol. 2020;21(5):645-654.
ZEPZELCA® (lurbinectedin) prescribing information. Jazz Pharmaceuticals, Palo Alto, CA, April 2022.
Subbiah V, Paz-Ares L, Besse B, et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer. 2020;150:90-96.
Armstrong DK, Spriggs D, Levin J, Poulin R, Lane S. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Oncologist. 2005;10(9):686-694.
Paz-Ares L, Ciuleanu T, Navarro A, et al. Lurbinectedin/doxorubicin versus CAV or topotecan in relapsed SCLC patients: phase III randomized ATLANTIS trial. Presented at the 2021 World Conference on Lung Cancer, September 8-14, 2021 (virtual). Abstract PL02.03.
Navarro A, Aix SP, Barneto-Aranda IC, et al. Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial. J Clin Oncol. 2022;40 (suppl; abstr 8524).
Calles A, Navarro A, Doger B, et al. A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study. J Clin Oncol. 2022; 40 (suppl 16):8581.
Kundu K, Cardnell RJ, Zhang B, et al. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. Transl Lung Cancer Res. 2021;10(11):4095-4105.
ClinicalTrials.gov. Testing maintenance therapy for small cell lung cancer in patients with SLFN11 positive biomarker. Available at: https://clinicaltrials.gov/ct2/show/NCT04334941 Accessed September 30, 2022.
ClinicalTrials.gov. Clinical trial of lurbinectedin as single-agent or in combination with irinotecan versus topotecan or irinotecan in patients with relapsed small-cell lung cancer (LAGOON). Available at: https://clinicaltrials.gov/ct2/show/NCT05153239 Accessed September 30, 2022.
ClinicalTrials.gov. A phase III, open-label study of maintenance lurbinectedin in combination with atezolizumab compared with atezolizumab in participants with extensive-stage small-cell lung cancer (IMforte). Available at: https://clinicaltrials.gov/ct2/show/NCT05091567 Accessed September 30, 2022.
Gao Y, Liu P, Shi R. Anlotinib as a molecular targeted therapy for tumors. Oncol Lett. 2020;20(2):1001-1014.
Wu D, Nie J, Hu W, et al. A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. Int J Cancer. 2020;147(12):3453-3460.
Deng P, Hu C, Chen C, et al. Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial. Cancer Med. 2022;10.1002/cam4.4736.
Liu C, Liao J, Wu X, et al. A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer. Thorac Cancer. 2022;13(10):1463-1470.
Xu H, Cao D, Jie F, et al. The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis. Tumori. 2022;3008916221082704.
Yuan J, Cheng F, Xiao G, et al. Efficacy and safety of anlotinib in the treatment of small cell lung cancer: a real-world observation study. Front Oncol. 2022;12:917089.
Kong T, Chen L, Zhao X, et al. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study. Invest New Drugs. 2022;40(5):1095-1105.
Hao YY, Qiao YP, Cheng JD. Clinical activity and safety of anlotinib combined with PD-1 blockades for patients with previously treated small cell lung cancer. Int J Gen Med. 2021;14:10483-10493.
ClinicalTrials.gov. A study of TQB2450 or placebo combined with anlotinib, etoposide and carboplatin versus etoposide and carboplatin in subjects with extensive small cell lung cancer (ETER701). Available at: https://clinicaltrials.gov/ct2/show/NCT04234607 Accessed September 30, 2022.
Liu Y, Hu X, Jiang J, et al. A prospective study of apatinib in patients with extensive-stage small cell lung cancer after failure of two or more lines of chemotherapy. Oncologist. 2020;25(5):e833-e842.
Xu Y, Huang Z, Lu H, et al. Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study. Br J Cancer. 2019;121(8):640-646.
Luo H, Zhang L, Yang B, et al. A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer. Invest New Drugs. 2020;38(1):148-159.
Yan X, Wang Q, Wang H, et al. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study. J Cancer Res Clin Oncol. 2019;145(1):235-240.
Landre T, Chouahnia K, Des Guetz G, et al. First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920977137.
ClinicalTrials.gov. Camrelizumab combined with apatinib, etoposide and cisplatin treat small-cell lung cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT04490421 Accessed September 30, 2022.
ClinicalTrials.gov. SHR-1210 combined with apatinib in treatment of ED-SCLC after failure of first line standard therapy (PASSION). Available at: https://clinicaltrials.gov/ct2/show/NCT03417895 https://clinicaltrials.gov/ct2/show/NCT04659785 Accessed September 30, 2022.
ClinicalTrials.gov. A study of fluzoparib combined with apatinib as second-line treatment of patients with extensive stage small cell lung cancer (FA-ES-SCLC). Available at: https://clinicaltrials.gov/ct2/show/NCT04659785 Accessed September 30, 2022.
ClinicalTrials.gov. Apatinib as the maintenance therapy for extensive stage small cell lung cancer after combined with etoposide/cisplatin. Available at: https://clinicaltrials.gov/ct2/show/NCT02875457 Accessed September 30, 2022.
Meijer JJ, Leonetti A, Airò G, et al. Small cell lung cancer: novel treatments beyond immunotherapy. Semin Cancer Biol. 2022:S1044-579X(22)00115-8.
Xiong J, Barayan R, Louie AV, Lok BH. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review. Semin Cancer Biol. 2022;S1044-579X(22)00179-1.
Knelson EH, Patel SA, Sands JM. PARP inhibitors in small-cell lung cancer: rational combinations to improve responses. Cancers (Basel). 2021;13(4):727.
Byers LA, Bentsion D, Gans S, et al. Veliparib in combination with carboplatin and etoposide in patients with treatment-naïve extensive-stage small cell lung cancer: A phase 2 randomized study. Clin Cancer Res. 2021;27(14):3884-3895.
Owonikoko TK, Dahlberg SE, Sica GL, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol. 2019;37:222-229.
Kaina B, Beltzig L, Strik H. Temozolomide - just a radiosensitizer? Front Oncol. 2022;12:912821.
Pietanza MC, Waqar SN, Krug LM, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol. 2018;36(23):2386-2394.
Farago AF, Yeap BY, Stanzione M, et al. Combination olaparib and temozolomide in relapsed small-cell lung cancer. Cancer Discov. 2019;9(10):1372-1387.
Gao B, Lin C-C, Bai L-Y, et al. A study of senaparib in combination with temozolomide for the treatment of patients with advanced solid tumors and extensive-stage small cell lung cancer. J Clin Oncol. 2022;40 (abstr 3102).
Hou W, Zhou X, Yi C, Zhu H. Immune check point inhibitors and immune-related adverse events in small cell lung cancer. Front Oncol. 2021;11:604227.
Berti A, Bortolotti R, Dipasquale M, et al. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. Crit Rev Oncol Hematol. 2021;162:103351.
Zhang W, Gu J, Bian C, Huang G. Immune-related adverse events associated with immune checkpoint inhibitors for advanced non-small cell lung cancer: A network meta-analysis of randomized clinical trials. Front Pharmacol. 2021;12:686876.
Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update [published correction appears in J Clin Oncol. 2022 Jan 20;40(3):315]. J Clin Oncol. 2021;39(36):4073-4126.
Schneider BJ, Lacchetti C, Bollin K. Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. JCO Oncol Pract. 2022;18(6):431-444.
Nightingale G, Hajjar E, Pizzi LT, et al. Implementing a pharmacist-led, individualized medication assessment and planning (iMAP) intervention to reduce medication related problems among older adults with cancer. J Geriatr Oncol. 2017;8(4):296-302.
Umar RM, Apikoglu-Rabus S, Yumuk PF. Significance of a clinical pharmacist-led comprehensive medication management program for hospitalized oncology patients. Int J Clin Pharm. 2020;42(2):652-661.
Choukroun C, Leguelinel-Blache G, Roux-Marson C, et al. Impact of a pharmacist and geriatrician medication review on drug-related problems in older outpatients with cancer. J Geriatr Oncol. 2021;12(1):57-63.
Mislang AR, Wildes TM, Kanesvaran R, et al. Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations. Cancer Treat Rev. 2017;57:58-66.
Gatwood J, Gatwood K, Gabre E, Alexander M. Impact of clinical pharmacists in outpatient oncology practices: A review. Am J Health Syst Pharm. 2017;74(19):1549-1557.
Bagwell A, Kelley T, Carver A, et al. Advancing patient care through specialty pharmacy services in an academic health system. J Manag Care Spec Pharm. 2017;23(8):815-820.
Mejías-De Jesús CM, Eche IJ. A nurse-pharmacist collaborative approach to reducing financial toxicity in cancer care. Clin J Oncol Nurs. 2022;26(1):114-119.
Miao J, Ji S, Wang S, Wang H. Effects of high quality nursing in patients with lung cancer undergoing chemotherapy and related influence on self-care ability and pulmonary function. Am J Transl Res. 2021;13(5):5476-5483.
Sun Y, Wang X, Li N, Bian J. Influence of psychological nursing and health education on depression, anxiety and life quality of elderly patients with lung cancer. Psychogeriatrics. 2021;21(4):521-527.
Shen Y, Zhou Y, Hou J, Hu J. Application effects of evidence-based nursing in pain nursing of advanced lung cancer. Am J Transl Res. 2021;13(8):9479-9484.
Wu Y, Yao J, Zhao J, Wang L. Effect of high quality nursing on alleviating negative emotions in patients with advanced lung cancer. Am J Transl Res. 2021;13(10):11958-11965.
Yu J, Huang T, Xu J, et al. Effect of nursing method of psychological intervention combined with health education on lung cancer patients undergoing chemotherapy. J Healthc Eng. 2022;2022:2438612.
Mackler E, Segal EM, Muluneh B, et al. 2018 Hematology/Oncology Pharmacist Association best practices for the management of oral oncolytic therapy: pharmacy practice standard. J Oncol Pract. 2019;15(4):e346-e355.
Ignoffo RJ, Knapp KK, Seung A, et al. Trends in the delivery of care to oncology patients in the United States: Emphasis on the role pharmacists on the healthcare team. J Oncol Pharm Pract. 2021;27(1):5-13.
Wangnum K, Thanarojanawanich T, Chinwatanachai K, et al. Impact of the multidisciplinary education program in self-care on fatigue in lung cancer patients receiving chemotherapy. J Med Assoc Thai. 2013;96(12):1601-1608.
Jewitt N, Hope AJ, Milne R, et al. Development and evaluation of patient education materials for elderly lung cancer patients. J Cancer Educ. 2016;31(1):70-74.